Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1960 1
1966 1
1974 1
1978 4
1979 1
1984 2
1985 3
1986 5
1987 4
1988 6
1989 3
1990 3
1991 4
1992 2
1993 3
1995 2
1996 1
1997 5
1998 5
1999 6
2000 5
2001 5
2002 3
2003 8
2004 6
2005 13
2006 17
2007 15
2008 14
2009 18
2010 20
2011 28
2012 23
2013 26
2014 25
2015 26
2016 41
2017 33
2018 30
2019 27
2020 32
2021 28
2022 38
2023 35
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

524 results

Results by year

Filters applied: . Clear all
Proximity search should include two or more words. Proximity operator ignored :~0
Page 1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Free article. Review.
MUTATIONS: SRSF2, ASXL1, and U2AF1-Q157 mutations predict inferior survival in PMF; RAS/CBL mutations predict resistance to ruxolitinib therapy. Type 1/like CALR mutation is associated with superior survival. ...Drug therapy in MF is currently palliative and targets …
MUTATIONS: SRSF2, ASXL1, and U2AF1-Q157 mutations predict inferior survival in PMF; RAS/CBL mutations predict resistance to ruxolitinib t …
Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Tefferi A, Barbui T. Tefferi A, et al. Am J Hematol. 2023 Sep;98(9):1465-1487. doi: 10.1002/ajh.27002. Epub 2023 Jun 26. Am J Hematol. 2023. PMID: 37357958 Review.
Cytoreductive therapy is reserved for high-risk disease with first-line drugs of choice being hydroxyurea and pegylated interferon-alpha and second-line busulfan and ruxolitinib. ...The current review also includes specific treatment strategies in the context of pregnancy, …
Cytoreductive therapy is reserved for high-risk disease with first-line drugs of choice being hydroxyurea and pegylated interferon-al …
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A. Tefferi A. Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2. Am J Hematol. 2021. PMID: 33197049 Free article. Review.
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations. ...ADVERSE MUTATIONS: SRSF2, ASXL1, and U2AF1-Q157 mu …
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myelop …
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A, Barbui T. Tefferi A, et al. Am J Hematol. 2020 Dec;95(12):1599-1613. doi: 10.1002/ajh.26008. Epub 2020 Oct 23. Am J Hematol. 2020. PMID: 32974939 Free article. Review.
All patients with PV require phlebotomy to keep hematocrit below 45% and once-daily or twice-daily aspirin (81 mg), in the absence of contraindications. Very low risk ET might not require therapy while aspirin therapy is advised for low risk disease. Cytoreductive …
All patients with PV require phlebotomy to keep hematocrit below 45% and once-daily or twice-daily aspirin (81 mg), in the absence of contra …
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A, Vannucchi AM, Barbui T. Tefferi A, et al. Am J Hematol. 2024 Apr;99(4):697-718. doi: 10.1002/ajh.27216. Epub 2024 Jan 25. Am J Hematol. 2024. PMID: 38269572 Review.
Cytoreductive therapy is advised for high-risk and optional for intermediate-risk disease. ...ADDITIONAL CONTENT: The current review includes specific treatment strategies in the context of extreme thrombocytosis, pregnancy, splanchnic vein thrombosis, perioperative car …
Cytoreductive therapy is advised for high-risk and optional for intermediate-risk disease. ...ADDITIONAL CONTENT: The current review …
Myelofibrosis biology and contemporary management.
Gangat N, Tefferi A. Gangat N, et al. Br J Haematol. 2020 Oct;191(2):152-170. doi: 10.1111/bjh.16576. Epub 2020 Mar 20. Br J Haematol. 2020. PMID: 32196650 Free article. Review.
Myelofibrosis is an enigmatic myeloproliferative neoplasm, despite noteworthy strides in understanding its genetic underpinnings. ...Our review serves to synopsise current appreciation of the pathogenesis of myelofibrosis together with emerging management strategies …
Myelofibrosis is an enigmatic myeloproliferative neoplasm, despite noteworthy strides in understanding its genetic underpinnings. ... …
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Stockklausner C, Duffert CM, Cario H, Knöfler R, Streif W, Kulozik AE; THROMKID-Plus Studiengruppe der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) and of Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH). Stockklausner C, et al. Ann Hematol. 2021 Jul;100(7):1647-1665. doi: 10.1007/s00277-021-04485-0. Epub 2021 Mar 12. Ann Hematol. 2021. PMID: 33712866 Free PMC article. Review.
Furthermore, somatic mutations in JAK2, MPL, and in the gene-encoding calreticulin (CALR) have been described to act as driver mutations within the so-called Philadelphia-negative myeloproliferative neoplasms (MPNs), namely essential thrombocythemia (ET), polycythemia vera (PV), …
Furthermore, somatic mutations in JAK2, MPL, and in the gene-encoding calreticulin (CALR) have been described to act as driver mutations wit …
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George TI, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. Gerds AT, et al. J Natl Compr Canc Netw. 2022 Sep;20(9):1033-1062. doi: 10.6004/jnccn.2022.0046. J Natl Compr Canc Netw. 2022. PMID: 36075392
The Guidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. ...This article focuses on the recommendations as …
The Guidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for …
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Barbui T, et al. Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Leukemia. 2018. PMID: 29515238 Free PMC article. Review.
Key differences from the 2011 diagnostic recommendations included: lower threshold values for hemoglobin and hematocrit and bone marrow examination for diagnosis of polycythemia vera (PV), according to the revised WHO criteria; the search for complementary clonal markers, such as …
Key differences from the 2011 diagnostic recommendations included: lower threshold values for hemoglobin and hematocrit and bone marrow exam …
Next Generation Therapeutics for the Treatment of Myelofibrosis.
Tremblay D, Mascarenhas J. Tremblay D, et al. Cells. 2021 Apr 27;10(5):1034. doi: 10.3390/cells10051034. Cells. 2021. PMID: 33925695 Free PMC article. Review.
JAK inhibitors are the only approved therapy for myelofibrosis and have been successful in reducing spleen and symptom burden. ...We also provide commentary on the future of therapeutic development in myelofibrosis....
JAK inhibitors are the only approved therapy for myelofibrosis and have been successful in reducing spleen and symptom burden. …
524 results